DT opens a North American subsidiary at Montreal’s NEOMED Institute.

Canada-based Domain Therapeutics NA Inc. will focus exclusively on leveraging the BioSens-All(TM) technology.

Domain Therapeutics, a biopharmaceutical company specializing in the research and development of new drug candidates targeting G protein-coupled receptors (GPCRs), today announces the opening of its North American subsidiary, Domain Therapeutics NA Inc., at the NEOMED Institute in Montreal, Canada…

Download PDF